close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Instinct Bio Technical Company Holdings Inc. - Common stock (NQ:BIOT)

0.4030 -0.0256 (-5.97%)
Streaming Delayed Price Updated: 3:22 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Instinct Bio Technical Company Holdings Inc. - Common stock

News headline image
Instinct Bio Announces Strategic Collaboration With INVITRX to Expand GENREVER Into U.S. and Advance Indonesia Regenerative Medicine Initiatives
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning! We're preparing for another busy day of trading with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
From Blade Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.